Ionis-AstraZeneca Heart Trial Fails; Analysts See Neutral-to-Negative Read-Through for Alnylam
Eplontersen failed to reduce heart events in 1,432 ATTR-CM patients. Results raise questions on silencer-plus-stabilizer use and for Alnylam’s pipeline.
/ 6 items
#ALNY↓
BMO Capital Initiates Coverage on 7 Biotech Stocks: Outperform Ratings for ALNY, ASND, BMRN & More
BMO Capital starts coverage on ALNY, ASND, BMRN, CATX & more with Outperform ratings and price targets. See full analyst insights and targets.
Alnylam Stock Crashes Nearly 30% as Company Lowers Full-Year Revenue Outlook
Alnylam cuts 2026 Amvuttra sales guidance to $4.2B–$4.5B due to slower growth in second-line ATTR-CM demand.
Wainua Trial Setback Sends Ionis Plunging and Drags Down AstraZeneca
AstraZeneca and Ionis’s Wainua missed its primary endpoint in the Phase 3 ATTR-CM trial, while competitors Alnylam and BridgeBio surged.
Alnylam Teams Up with ChatGPT Creator’s AI Company to Revolutionize RNAi Therapeutics
Alnylam Pharmaceuticals partners with AI startup Inceptive in a deal worth up to $2 billion to accelerate discovery of next-generation RNAi therapeutics using powerful AI models.
Billion-Dollar Hearts: Tenaya and Alnylam Join Forces to Target Genetic Causes of Cardiovascular Disease
Tenaya Therapeutics partners with Alnylam to discover new genetic targets for heart disease treatments, potentially earning up to $1.13 billion in milestones.